These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 9164416)

  • 41. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
    Greiner B; Eichelbaum M; Fritz P; Kreichgauer HP; von Richter O; Zundler J; Kroemer HK
    J Clin Invest; 1999 Jul; 104(2):147-53. PubMed ID: 10411543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
    Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E
    Clin Pharmacol Ther; 2011 Sep; 90(3):406-13. PubMed ID: 21814190
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
    Morse GD; Fischl MA; Shelton MJ; Cox SR; Driver M; DeRemer M; Freimuth WW
    Antimicrob Agents Chemother; 1997 Jan; 41(1):169-74. PubMed ID: 8980774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers.
    Chik Z; Basu RC; Pendek R; Lee TC; Mohamed Z
    Clin Ther; 2010 Sep; 32(10):1822-31. PubMed ID: 21194606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increase in urinary excretion of 6beta-hydroxycortisol in common marmosets as a marker of hepatic CYP3A induction.
    Totsuka S; Watanabe T; Koyanagi F; Tanaka K; Yasuda M; Manabe S
    Arch Toxicol; 1999; 73(4-5):203-7. PubMed ID: 10463384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers.
    Ferry JJ; Herman BD; Carel BJ; Carlson GF; Batts DH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):252-9. PubMed ID: 9665503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects.
    Dimmitt DC; Cramer MB; Keung A; Arumugham T; Weir SJ
    Cancer Chemother Pharmacol; 1999; 43(2):126-32. PubMed ID: 9923817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients.
    Shelton MJ; Hewitt RG; Adams J; Della-Coletta A; Cox S; Morse GD
    Antimicrob Agents Chemother; 2003 May; 47(5):1694-9. PubMed ID: 12709342
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
    Freimuth WW
    Adv Exp Med Biol; 1996; 394():279-89. PubMed ID: 8815692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delavirdine: clinical pharmacokinetics and drug interactions.
    Tran JQ; Gerber JG; Kerr BM
    Clin Pharmacokinet; 2001; 40(3):207-26. PubMed ID: 11327199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Midazolam and cortisol metabolism before and after CYP3A induction in humans.
    Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y
    Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.
    Morse GD; Reichman RC; Fischl MA; Para M; Leedom J; Powderly W; Demeter LM; Resnick L; Bassiakos Y; Timpone J; Cox S; Batts D
    Antiviral Res; 2000 Jan; 45(1):47-58. PubMed ID: 10774589
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
    Elsherbiny D; Cohen K; Jansson B; Smith P; McIlleron H; Simonsson US
    Eur J Clin Pharmacol; 2009 Jan; 65(1):71-80. PubMed ID: 18751690
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of rifampin on tocainide pharmacokinetics in humans.
    Rice TL; Patterson JH; Celestin C; Foster JR; Powell JR
    Clin Pharm; 1989 Mar; 8(3):200-5. PubMed ID: 2495879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.
    Smith PF; Dicenzo R; Forrest A; Shelton M; Friedland G; Para M; Pollard R; Fischl M; DiFrancesco R; Morse GD
    Clin Pharmacokinet; 2005; 44(1):99-109. PubMed ID: 15634033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.
    Loboz KK; Gross AS; Williams KM; Liauw WS; Day RO; Blievernicht JK; Zanger UM; McLachlan AJ
    Clin Pharmacol Ther; 2006 Jul; 80(1):75-84. PubMed ID: 16815319
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism.
    Holtbecker N; Fromm MF; Kroemer HK; Ohnhaus EE; Heidemann H
    Drug Metab Dispos; 1996 Oct; 24(10):1121-3. PubMed ID: 8894514
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin.
    Conte JE; Golden JA; Kipps JE; Lin ET; Zurlinden E
    Clin Pharmacokinet; 2004; 43(6):395-404. PubMed ID: 15086276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic and safety evaluation of the use of ciprofloxacin on an isoniazid-rifampicin regimen in rabbits.
    Padilha EC; Pires RV; Filho MA; de Pontes Machado DV; Baldan HM; Davanço MG; Campos ML; Brunetti IL; Peccinini RG
    Biopharm Drug Dispos; 2012 Dec; 33(9):501-9. PubMed ID: 23007681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liquid chromatographic determination of urinary 6beta-hydroxycortisol to assess cytochrome p-450 3A activity in HIV positive pregnant women.
    Homma M; Beckerman K; Hayashi S; Jayewardene AL; Oka K; Gambertoglio JG; Aweeka FT
    J Pharm Biomed Anal; 2000 Sep; 23(4):629-35. PubMed ID: 10975239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.